LUNG AND RESPIRATORY SYSTEM DISEASES (E.G., ASTHMA, EMPHYSEMA)
Keywords:
Asthma, Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Airway inflammation, Alveolar destruction, Respiratory diseases, Bronchodilators, Inhaled corticosteroids.Abstract
Lung and respiratory system diseases, such as asthma and emphysema, represent significant global health challenges due to their prevalence, impact on quality of life, and economic burden. Asthma, a chronic inflammatory disorder of the airways, and emphysema, a progressive disease characterized by the destruction of the alveolar walls, are two common respiratory conditions that affect millions of people worldwide. This paper explores the pathophysiology, mechanisms, and clinical implications of asthma and emphysema, discussing their etiology, diagnosis, and treatment options. Through a detailed review of the existing literature, this paper aims to provide a comprehensive understanding of these diseases and the latest advancements in their management.
References
1.Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and Prevention.
2.Wenzel, S. E., et al. (2018). "The Role of Eosinophils in Asthma." Journal of Allergy and Clinical Immunology, 142(4), 973-980.
3.Corren, J., et al. (2020). "Dupilumab Treatment in Severe Asthma with Elevated Eosinophil Counts." The New England Journal of Medicine, 382(1), 1-13.
4.Hogg, J. C., et al. (2017). "The Pathogenesis of Emphysema: Role of Proteases and Antiproteases." Chest, 151(6), 1206-1214.
5.Stoller, J. K., et al. (2019). "Alpha-1 Antitrypsin Deficiency and the Pathogenesis of Emphysema." American Journal of Respiratory and Critical Care Medicine, 200(6), 670-678.
6.Tashkin, D. P., et al. (2020). "The Role of Bronchodilators in COPD Management." The Lancet Respiratory Medicine, 8(4), 347-357.
7.Salvi, S. S., & Agusti, A. (2017). "Smoking and COPD: Mechanisms of Disease, Pathophysiology, and Therapeutic Approaches." Lancet Respiratory Medicine, 5(1), 7-18.
